Allegra J. Padula

Allegra Padula is an associate in the firm’s Litigation department. She joined Goodwin in 2024. Allegra focuses her practice on patent litigation in the life sciences and technology sectors. She is registered to practice before the U.S. Patent and Trademark Office (USPTO).

Allegra has served clients in matters involving various industries, including pharmaceutical sciences and biotechnology. She has experience representing companies in litigation under the Biologics Price Competition and Innovation Act (BPCIA).

She is a contributor to the firm’s Big Molecule Watch, an award-winning blog that reports real-time analysis and updates on regulatory issues, litigation, legislation, and other news in the developing world of biosimilars. She also contributes to Goodwin’s PTAB Trial Tracker.

Allegra maintains an extensive pro bono practice, including working with the New England Innocence Project, the ACLU of Massachusetts, and the Boston Area Rape Crisis Center.

Allegra is a member of the Boston Bar Association.

Prior to joining Goodwin, Allegra served as a Judicial Intern for the Honorable Lawrence E. Kahn, Senior United States District Court Judge for the Northern District of New York. During law school, Allegra worked part-time as a Law Clerk at a boutique intellectual property law firm and served as a Legal Intern at the Research Foundation for SUNY, where she performed patentability and market opportunity assessments of cutting-edge technologies. She was a Summer Associate at Goodwin in 2023.

While in law school, Allegra served as Executive Editor for Research & Business on the Albany Law Review and as Collegiate Competitions Chair on the Anthony V. Cardona ’70 Moot Court Board. She competed in the Karen C. McGovern Senior Prize Trials Competition, finishing as a quarterfinalist. She was a member of the inaugural class of Women’s Leadership Initiative Fellows at Albany Law School.

Allegra earned her bachelor’s degree in Molecular Biology and conducted genetics research at Colgate University, focusing on the molecular analysis of development in C. elegans, using CRISPR-Cas9 and other molecular biology techniques. She co-authored a scientific publication and presented her research findings at various conferences at the state and international levels.

• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2025–2026 ed.,” published by Thomson Reuters, January 2026.
• Author, “23andMe . . . And You: Examining the Existence of a Patient’s Duty to Inform Family Members of Genetic Test Results and Establishing a New Cause of Action,” 87 Alb. L. Rev. 423, 2024.
• Co-Author, “The Doubletime Homolog KIN-20 Mainly Regulates let-7 Independently of Its Effects on the Period Homolog LIN-42 in Caenorhabditis elegans,” G3: Genes, Genomes, Genetics, 2018.

Thought Leadership

• Speaker, “Prosecution and Litigation Trends and Takeaways from BPCIA Litigation,” Goodwin Webinar, March 2025.
• Speaker, “The BPCIA Has Changed How Companies Should Be Protecting Innovative Biologics and Biosimilars: Has Your Company Changed Its Strategy?” Goodwin Webinar, November 2025.